6b). These results indicated that TLT-2 expression was down-regulated after activation. We further investigated cytokines that affect TLT-2 expression. Although IL-2, IFN-γ, TNF-α and IL-10 did not clearly affect TLT-2 expression on CD8+ T cells stimulated with anti-CD3 mAb, the addition of TGF-β markedly decreased the TLT-2 expression (Fig. 6c). Finally, we examined whether TLT-2 over-expressed on CD8+ T cells directly enhanced antigen-specific cytotoxicity against B7-H3-transduced tumour cells. TLT-2 was retrovirally transduced into OT-I CD8+ T cells and cytotoxicity against parental E.G7 or B7-H3/E.G7

was measured. The mean this website fluorescence intensity of TLT-2/GFP-transduced OT-I CD8+ T cells was sixfold higher than that of mock/GFP-transfected cells (Fig. 6d). selleck kinase inhibitor The transduction of TLT-2 did not

alter the activation status assessed by cell size and proliferation and IFN-γ production stimulated with anti-CD3 or phorbol 12-myristate 13-acetate plus ionomycin (data not shown). TLT-2-transduced OT-I CD8+ T cells showed higher cytotoxicity against both E.G7 and B7-H3/E.G7 than the mock-transduced OT-I CD8+ T cells. B7-H3 over-expression on tumours did not dramatically enhance cytotoxicity when there was sufficient TLT-2 expression on OT-I CD8+ T cells. These results suggest that TLT-2, which is expressed on CD8+ T cells, enhanced antigen-specific cytotoxicity by direct interaction with B7-H3 on tumour cells. We demonstrated that CD8+ T cells showed higher antigen-specific cytotoxicity against B7-H3-transduced tumour cells in vitro, and that B7-H3-transduced tumour cells were preferentially eliminated in vivo. The presence of B7-H3 on tumours during antigen sensitization did

not enhance the induced cytotoxicity against Carbohydrate alloantigen and OVA, whereas the presence of B7-H3 on target tumour cells did efficiently enhance the cytotoxicity. Transduction of B7-H3 into five different types of tumours markedly reduced their tumorigenicity, and the inoculated tumours were largely eradicated. Administration of either anti-B7-H3 or anti-TLT-2 mAb accelerated parental tumour growth, but not growth of B7-H3-transduced tumours. The RLN CD8+ T cells from tumour-bearing mice expressed substantial levels of TLT-2, but a considerable proportion of CD8+ T cells within TIL lost TLT-2 expression. Finally, TLT-2-transduced OT-I CD8+ T cells displayed greater cytotoxicity against both parental and B7-H3-transduced tumour cells. Because B7-H3 expression is ubiquitous,1,42 all tumour cell lines examined expressed endogenous B7-H3 at low-to-moderate levels. We transduced B7-H3 into such tumour cells and obtained the B7-H3 transfectants that expressed at least a 20-fold higher level of B7-H3 than parental cells, as assessed by fluorescence intensity.